1. Introduction {#s0005}
===============

Sickle cell disease (SCD) is a major health problem in many countries around the world. According to the World Health Organization ([@b0165], [@b0175], [@b0170]), every year nearly 300,000 to 500,000 infants are born with severe haemoglobin disorders, and more than 200,000 people born with sickle cell anaemia. These diseases were found to be less prevalent in southern India, Saudi Arabia, Mediterranean countries and Middle Eastern countries.

Hereditary blood diseases like SCD are caused by molecular changes in specific blood proteins called globins. Globins are the main component of haemoglobin, found in red blood cells. Haemoglobin is made up of four chains of globins, each of which carries the heme group, which is made up of Fe + Fe, which is associated with oxygen ([@b0135]). SCD is one of the most serious of the red blood cell disorders, and is caused by a abnormal haemoglobin known as HbS ([@b0035]). While normal red blood cells can survive for up to 120 days, sickle cells die in just 20 days. SCD results from a basal substitution of adenine A to thymine T in the sixth codon of beta-globin. The mutation of a single base in the DNA leads to the replacement of glutamic acid with valine in the polypeptide of the beta-globin chain in the haemoglobin S (HbS).

SCD is characterized by chronic haemolysis, recurrent vasoconstriction, rapid infection, failure of various organs in the body, a periodic pain, inflammation, stroke, and acute chest pain, abnormal haemoglobin in red blood cells, causing them to lose their flexibility and turn into the form of solid sickles ([@b0120]). Chronic haemolysis can lead to varying degrees of anaemia, jaundice, biliary tuberculosis, delayed growth and sexual maturity. Patients are also sensitive for the highest rates of pulmonary arterial haemorrhage, hypertension, rheumatism and leg ulcers ([@b0050], [@b0145], [@b0040], [@b0005]).

In Saudi Arabia, the SCD was first identified in the eastern region in 1960 by Lehman ([@b0115], [@b0160]), which led to the initiation of multiple studies at the regional and national level to determine the clinical characteristics and gene replication of SCD in different regions of Saudi Arabia. SCD is more common hereditary disorder in this part of the world, ranging from 0-4-8% while SCD carriers ranged from 2% to 27%. These estimates do not include neonatal screening, which may increase the real frequency of the disease ([@b0105]). Statistical analysis showed that there are about 3 million people had these genetic blood diseases in the Saudi Arabia, of which 30% in the Eastern Region ([@b0015]). El-Hazmi and others reported two different types of sickle cell anaemia, the average type of acute disease in most patients in the Eastern Region, while the severe type was observed in most patients in the southwestern region ([@b0085], [@b0090], [@b0060], [@b0075], [@b0080], [@b0065], [@b0070], [@b0020]).

The aim was to study the nucleotide sequences and the molecular survey of the β-globin gene in Saudi patients with sickle cell anemia, and to identify the genetic variants associated with clinical manifestations.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

The study was conducted on 77 of sickle cell anemia patients selected randomly from the attending the blood diseases clinic at King Khalid University Hospital (KKUH, Riyadh, KSA) from different regions of Saudi Arabia between Jan 2015 - June 2017. Hematological and biochemical measurements and history of each patient were investigated. The study protocol respected the most recent Declaration of Helsinki, written informed consent and Research Ethics Committee approval were obtained for all cases.

2.2. Sample {#s0020}
-----------

Ten ml of venous blood was withdrawn from each patient and distributed to two tubes (each containing 5 ml) of ethylenediamine tetra acetic acid (EDTA). The analyzers used in this study were Advia 2120 from Siemens Company for measuring hematology markers and Architect from Abbott Company for measuring biochemical markers.

2.3. Extraction of DNA {#s0025}
----------------------

DNA was extracted using a Qiagen gel purification kit, according to the manufacturer's instructions.

2.4. Primers & PCR {#s0030}
------------------

Primers were designed, requested and obtained through the Oligo ordering online. PCR primers were used (see [Table 1](#t0005){ref-type="table"}). Thirty-five cycles of PCR, with denaturation at 94 °C for 30 s, annealing at 60° C for 1 min, and extension at 72 °C for 1 min, were performed on a programmed-temperature system (Hybaid OmniGene; Midwest Scientific, Missouri, United States). After PCR amplification, 10 µl of the PCR products were mixed with 2 µl DNA loading buffer and electrophoresed on a 2 percent agarose gel containing 0.2 µg/ml ethidium bromide in 0.5X TBE buffer. A DNA ladder was also run in parallel. The amplified gel was visualized and photographed under UV light (Bio-Rad Gel Doc 2000 Imaging System).Table 1The primers that were designed and used in this study to multiply the beta-globin gene.Gene/FragmentPrimer seq 5′ -- 3′Product size (b.p)HBB-1FGtatgcctgggcttttgatg482HBB-1RCcctgtttcacatccctgatHBB-2FGcattttctttgacccagga488HBB-2RAcctgtctcaaccctcatcaHBB-3FCcaaacactttctgcgtgtg494HBB-3RGcagagttctgcttcctgctHBB-4FTgagaccctacgctgacctc458HBB-4RCaatggggtaatcagtggtgHBB-5FTtttgttcccccagacactc471HBB-5RTcttcctgcgtctccagaatHBB-6FTttttcttttcttaccagaaggtttt470HBB-6RTgctcctgggagtagattggHBB-7FActcctaagccagtgccaga490HBB-7RCAGATCCCCAAAGGACTCAAHBB-8FGgcactgactctctctgccta496HBB-8RAaaaattgcggagaagaaaaaHBB-9FTgttttcttttgtttaattcttgcttt486HBB-9RTtgctattgccttaacccagaHBB-10FTtcagggcaataatgatacaatg500HBB-10RGATGCTCAAGGCCCTTCATAHBB-11FTTCCTTTGTTCCCTAAGTCCAA489HBB-11RGgaacacttcaggggaaaggHBB-12FTgcatctctcagccttgact600HBB-12RCttgagactcatattttatttccaga

2.5. Statistical analysis {#s0035}
-------------------------

The data obtained was subjected to a statistical analysis using Window Excel and SPSS v17 statistical tools. ANOVAs tests for multiple comparisons and significant analysis (p \< 0.05) were carried out.

3. Results {#s0040}
==========

The study was conducted on 77 patients with sickle cell anemia attending blood diseases clinic at King Khalid University Hospital (KKUH) from different regions of Saudi Arabia. A comprehensive database was created including the patient\'s name, patient history, and biochemical and hematological tests ([Table 2](#t0010){ref-type="table"}). In addition, a number of modern and advanced molecular techniques were used to identify the genetic basis of the disease through the molecular survey of the nucleotide sequences of beta-globin and the entire gamma control areas within chromosome 11. [Fig. 1](#f0005){ref-type="fig"} shows the nature of the patients with sickle cell anemia. 82% of the patients were homozygous, 14% were gametes, and 4% had thalassemia.Table 2Hematological and biochemical measurements from SCA patients.WBCHgbPltLDHBilirubinMean11.3391.67368.24446.2448.18Median10.559534643237Std. Deviation4.8923.02165.67206.4040.06Minimum0.38.5441366Maximum311367771000243Percentiles258.5381.5260.75282.3329.55010.5595346432377514.23106.3467.75584.7552.67Fig. 1Patients characteristics on this study.Fig. 2Adding the T-base indicates the arrow to the location specified. \* C.-2454- / t Ins.

3.1. Clinical and blood data in the research sample: {#s0045}
----------------------------------------------------

[Table 2](#t0010){ref-type="table"} presents a summary of hematological and biochemical measurements from patients with sickle cell anemia that have been followed for more than 30 months.

3.2. WBC count {#s0050}
--------------

As shown in the [Table 3](#t0015){ref-type="table"}, there was a significant difference between those individuals with HBBF8_3 mutation and who don't. In other words, the presence of this mutation may cause an increase in the WBC count compared-globinTable 3Relationship between WBC count and mutation.![](fx1.gif)

3.3. Hemoglobin level {#s0055}
---------------------

As shown in [Table 4](#t0020){ref-type="table"}, there was a significant difference between those with mutations in HBBF4-3, HBBF5-1, HBBF8-2, HBBF12-1, HBBF12-3, compared to the control group.Table 4Relationship between Hb level count and mutation.![](fx2.gif)

3.4. Platelets {#s0060}
--------------

As shown in [Table 5](#t0025){ref-type="table"}, there was a not statistical difference between those with mutations and the control group.Table 5Relationship between Platelets count and mutation.Part/VariablePlateletsMeanMedianStandard DeviationHBBF2_2Normal368.45343.50159.60Mutated366.57431.00222.42HBBF4_3Normal372.89354.00171.03Mutated332.36341.00119.97HBBF5_1Normal368.99354.00157.90Mutated353.67307.00335.44HBBF7_4Normal373.38346.00164.59Mutated295.00293.50188.76HBBF8_2Normal370.48346.00158.72Mutated347.67322.00238.19HBBF8_3Normal363.36343.50171.88Mutated396.44366.00128.30HBBF9_1Normal372.78363.50170.17Mutated333.21341.00130.56HBBF12_1Normal372.42354.00161.18Mutated321.40307.00226.91HBBF12_2Normal358.44343.50151.02Mutated443.86488.00255.90HBBF12_3Normal366.52346.00156.89Mutated379.63359.50228.53

3.5. Level of lactate dehydrogenase (LDH) {#s0065}
-----------------------------------------

As shown in [Table 6](#t0030){ref-type="table"}, there was a significant difference between those with mutation in HBBF9-1, HBBF12-1, compared to the control group.Table 6Relationship between LDH level and mutation.![](fx3.gif)

3.6. Bilirubin level {#s0070}
--------------------

As shown in [Table 7](#t0035){ref-type="table"}, there was a significant difference between those with a mutation in HBBF9-1 compared to normal individuals (i.e, this mutation can increase bilirubin level).Table 7Relationship between Bilirubin level and mutation.![](fx4.gif)

Using Mann-Whitney test to determine whether there is a relationship between the parameters including: WBC, HB, PLT, LDH, Bilirubin and those individuals with mutations, [Table 8](#t0040){ref-type="table"} showed significant effect of some mutations on those individuals examined Hb, Platelets, and Bilirubin.Table 8Relationship between Lab parameters and SCD mutation.![](fx5.gif)

In this study, the beta-globin gene was divided into 12 overlapping segments covering all regions of the gene from exons and introns ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"}, [Fig. 12](#f0060){ref-type="fig"}, [Fig. 1](#f0005){ref-type="fig"}). The molecular assessment of the entire gene fraction was performed and compared to the gene reference using DNA star-Lasergene® software. The primary disease mutation was confirmed in all patients at the beginning of the seventh piece Hbb / Fragment 7: (C.20 GAG \> GTG A \> T EtoVRs \# 77121243). These changes were widely varied between substitution in different nitrogen bases, either by deletion, or Insertion. The number of changes identified in the beta-globin area was 47. These changes were matched by the mutations documented in the global database at: (<http://www.ensembl.org>) to identify new changes that do not have a reference number (RS).Fig. 3A new change identified in the fourth piece of the beta-glubin gene, the addition of base G at the indicated site \* C. -1432--14333 - / G Ins.Fig. 4A change identified in the fourth piece of the beta-gluten gene, a homozygous homozygous replacement of base G at base A at the indicated location \* C. -1119 G \> A Rs. 1,003,586.Fig. 5A change identified in the fourth piece of the beta-gluten gene, a heterozygous replacement of base G of base A at the indicated location \* C. -1119 G \> A Rs. 1,003,586.Fig. 6Changes identified in the sixth segment of the beta-gluten gene, a substitution between two bases at the specified location \*c-240 G \> A.Fig. 7A new change was identified in the seventh piece of the beta-globin gene, a deletion in two bases at the specified location C.25 to27 AA / - homo del.Fig. 8A new change identified in the ninth piece of the beta-gluten gene, a heterozygous replacement of the gamma-G base of the adenine A base at the specified location C.316-225G \> A.Fig. 9A new change identified in the ninth piece of the beta-gluten gene, a heterozygous replacement of the gamma-G base of the adenine A base at the specified location C.315 + 282G \> A.Fig. 10A new change identified in the tenth piece of the beta-gluten gene, which is a replacement of the G-cell base G with the thymine T base at the specified location C.212 G \> T.Fig. 11A change identified in the tenth piece of the beta-gluten gene, which replaces the adenine A base with the Gouanine G base at the specified location \* C. + 828 G \> A.Fig. 12A change was found in the twelve part of the beta-glubin gene, a replacement of the G base with the C base at the specified location \*C. + 786C \> G.

One change was identified in the first segment of the beta-globin gene ([Fig. 2](#f0010){ref-type="fig"}), which represents the introduction or addition of the thymine (T) base to the original gene sequence at site 2454 and was found in one patient at (1.3%: c.-2454- / T homo ins). A new change not previously registered in the global reference database.

The second segment of the gene was found to have three changes: heterozygous replacement of adenine base with the cytosine base (het. \* C- 1917c \> t) in about 10% of our samples, homologous replacement at the same site by (1.3% homo. 1917c \> t), and heterozygous replacement of (het. \* C.- 1934c \> a), replacing the adenine base with the cytosine base. New changes were found namely (-1119 G \> A homo) repeated in eight patients, followed by heterozygous change in the same location (\* c. -1119 G \> A het) repeated in three patients, followed by homozygous change (\* C. -1039C \> G) repeated in two patients. In the sixth segment of the gene, two changes were identified in the same location; former one is recorded at high frequency (in 96%: c-390 C \> T homo), the later is (4%: \* c-390 C \> T het). The seventh segment of beta-globin was an important discovery in this study, the mutation was found in all subjects of our study 100%. The changes are new and have not been recorded in the reference database, which are deletion of two bases (c.25 to 27 AA / - homo.del. −2544 G \> A), while the changes were made (c.118 CAG \> TAG C \> T Q40) end, (c. 93 + 1 G \> C) and found in three patients. While the ninth segment has two new changes that were not recorded previously namely: heterozygous substitutions in two different locations (c.316-225G \> A het) and (het.c.315 + 282G \> A). In the tenth segment, two replicates were found in all individuals of our samples (100%, c.316--185 C \> T het). This change was a silent mutation: (het. C.396 CAG \> CAA G \> A Q132Q).

4. Discussion {#s0075}
=============

In the past three decades, many studies have focused on the clinical and biochemical features of SCD in Saudi patients, some of which have targeted specific mutations in beta-globin in Saudi patients ([@b0085], [@b0090], [@b0060], [@b0075], [@b0080], [@b0065], [@b0070]), while Al-Shehri's group examined the whole beta-globin gene ([@b0025]) to identify the specific mutations in Saudi patients. Our current study was designed to investigate the complete β-globin gene, which is about 3.8 Kb including UTR untranslated regions 5 and 3, and all oxons and introns, in order to identify all mutations and genetic changes in SCD.

[@b0095] reported interesting results in his study on the prevalence of sickle cell anaemia and thalassemia in Al-Qassim region, where they showed that the prevalence of thalassemia beta and sickle cell anaemia to be 0.165% and 0.252% respectively. [@b0040] also showed that the clinical manifestations of sickle cell disease vary widely among patients, where some patients with sickle cell anaemia have mild disease, while others suffer from a severe form and relatively high mortality at early age.

Our current results were obtained from 77 SCD patients at the KKUH from various regions of Saudi Arabia, exhibiting a wide spectrum of the disease from mild to severe stages. This was evidenced by the follow-up of several indicators in patients\' records throughout the study period. The differences in SCD patients were related to the need for medical emergency assistance, as well as the need to stay at the hospital for several days to receive the necessary treatment.

During the follow-up of 48 SCD patients, we monitored more than 69 pain crisis in 21 individuals. The vast majority of follow-up SCD patients were treated at the emergency department, while a few were admitted to the hospital. It was clear that the clinical symptoms of our patients vary greatly, as reported by [@b0130].

The beta-globin gene is located on chromosome 11 and consists of three exons separated by two interconnected sequences of introns known as "IVS". Mutations at introns (IVS-1, IVS- 2) may have a significant effect on the gene expression of the beta-globin gene ([@b0155]).

The genetic survey of the beta-globin gene in our sample showed a wide range of changes (48 changes including: eight new changes not included in the global database). These changes varied widely between different nitrogen bases (*c. + 828 G \> A het) , (c. + 786 C \< G homo) and (c. + 786 C \< G het).* It was found that the last three changes Were new and did not have reference figures. It was also found that some of these observed mutations were statistically and strongly correlated with one or more of the clinical symptoms.

A close relationship between the clinical homogeneity of SCD and haemoglobin levels was found (40.16%. -1119 G \> A homo./het. Rs \# 1003586). LDH is a clinically significant indicator of haemolysis and was associated with a decreased haemoglobin levels in our patients, ([@b0045]). Moreover, the bellowed changes were also associated with an increase in the WBCs count in our study: (rs \# 10768683c. 315 + 16 G \> C homo).

Préhu's group suggested a strong relationship between low oxygen levels, SCD and this change (1119 G \> A homo./het. Rs \# 1003586), and this has been supported by a previous study ([@b0125]), which also linked the same change with an increase in the number of white blood cells (WBCs).

The change (rs \# 10,742,583 \* c-390 C \> T homo./het), was demonstrated in the sixth segment of the gene in all patients, but did not appear in the control group, while the change (rs \# 34188626c.396 CAG \> CAA G \> A Q132Q het), in the tenth segment, appeared to affect the severity of the disease, and is a silent mutation.

In the eighth segment of the gene, the change (c.315 + 1 G \> A het), was related to the levels of HbF, which has a role in improving the clinical severity of SCD patients. There were also new changes in the eighth region among our patients but not in the control group by 3.9%: (*c.315 + 26 T \> G het),* (*c.315 + 1 G \> A het) and* (*c.- 1039C \> G homo./het.rs\# 16911905).* In the twelfth segment of the gene, there was a new change that has not been observed in the Global Human Genome Database (100%) in both groups. New unregistered changes in the database were found by 1% in the study: *(\*c.-2454-/t homo ins), (\*c. −1432*--*14333 -/G homo ins), (\*c.-986 A \> G het), (\*c753 T \< C homo), (c.25 to27 AA/\-- homo del), (\*c. −2544 G \> A het), (\*c. −2544 G \> A het), (c.315 + 282G \> A het), and (c.212 G \> T het).*

Another change was demonstrated in the tenth segment of the gene in all patients as well as the control group (c.316--185 C \> T het). This change has been confirmed by Trecarinet's study, where they investigated the genetic survey of thalassaemic patients from Mediterranean and Turkish individuals ([@b0150]).

Ahmed's group showed elevation in WBC count in 50% of SCD patients and were with lowered Hb concentration. They concluded that a special strategies to lower WBC in order to prevent disease complications ([@b0010]). Habara et al. reviewed the genetic basis and disease severity of SCD and suggested that huge efforts to be made for the treatment and counseling ([@b0100]). Damanhouri et al showed that SCD patients have many clinical features such as: hypercoagulapathy, hemolysis, inflammation, oxidation stress, vasoculopathy and reduced vasodilatory response. Their blood counts and urine are similar to ours ([@b0055]). Steinberg et al found 4 SNPs namely (rs3834466; rs28440105; rs10128556; rs968857) using RFLP technology ([@b0140]). Alsultan's group assessed 104 SCD patients and found that 96% have pain, 47% have chest infection, 18% have osteonecrosis, 66% with gallstone, 33% with G6PD deficiency, and 7% with stroke ([@b0030]). Kalai et al found that rs1984112 is associated with high reticulocytosis count in SCD patients, allowed earlier and reliable biomarkers for vascular occlusions ([@b0110]).

In conclusion, SCD had profound negative effects on many organs, causing many complications. The above results should be taken further to set up management strategies to improve outcomes.
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